Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

November 25, 2013 | APPEARED IN VOLUME 91, ISSUE 47

Merck KGaA has increased its ownership in Jerusalem-based lighting technology start-up Qlight Nanotech. Merck is working with Qlight to apply the start-up’s semiconductor nanoparticles, known as quantum dots, for use in next-generation display screens.

Frutarom, an Israeli flavors and fragrances firm, has bought a 75% stake in Russian food ingredients firm Protein Technologies Ingredients Group for $50 million. PTI develops and markets savory flavors, seasonings, and functional raw materials for processed meats and convenience foods.

Thermo Fisher Scientific will issue 5.3 million shares to Temasek, a Singapore government-owned investment firm, for $500 million. The money will be used to finance the planned $13.6 billion acquisition of life sciences industry supplier Life Technologies.

Agilent Technologies has introduced a new version of its electronic laboratory notebook software that enables scientists to capture and manage data obtained from other analytical software applications in a laboratory. OpenLab ELN 4.2 also features a printing function that allows users to format data from diverse applications into a PDF without leaving the notebook application.

Janssen Pharmaceuticals, the pharmaceuticals arm of Johnson & Johnson, will pay Vertex Pharmaceuticals $152 million for the product royalty rights to the hepatitis C treatment Incivo. The companies partnered in 2006 to develop Incivo in Europe and other markets, where Janssen now has sole ownership of the drug.

Aileron Therapeutics has raised $30 million from existing investors, including the venture arms of Eli Lilly & Co., Glaxo­SmithKline, Novartis, and Roche. The Cambridge, Mass.-based company will use the money to support clinical development of its stapled peptide drugs.

Alliqua has entered a licensing agreement with Celgene Therapeutics, giving Alliqua the rights to develop and market Celgene’s advanced wound-care products Biovance and Extracellular Matrix. Celgene will also purchase $6 million in Alliqua stock.

Sanofi has stopped clinical studies and ended plans to ask regulatory authorities to approve fedratinib, a JAK2 inhibitor in Phase III studies to treat myelofibrosis, a rare cancer of the bone marrow. The decision was prompted by instances of Wernicke’s encephalopathy, a neurological disorder caused by depletion of B vitamins.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment